Published in J Clin Invest on January 01, 2008
Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer (2010) 5.26
The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res (2008) 2.21
Spatial organization of transmembrane receptor signalling. EMBO J (2010) 2.03
Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin Ther Targets (2011) 1.65
A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol Cell Biol (2009) 1.54
Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res (2012) 1.47
Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res (2009) 1.44
Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development. Breast Cancer Res (2009) 1.40
Kaposi's sarcoma-associated herpesvirus interacts with EphrinA2 receptor to amplify signaling essential for productive infection. Proc Natl Acad Sci U S A (2012) 1.38
Eph receptor signaling and ephrins. Cold Spring Harb Perspect Biol (2013) 1.33
Chemosensitization of cancer cells by siRNA using targeted nanogel delivery. BMC Cancer (2010) 1.31
Ephexin4 and EphA2 mediate cell migration through a RhoG-dependent mechanism. J Cell Biol (2010) 1.24
ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. Cancer Res (2011) 1.23
Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome. PLoS One (2011) 1.22
Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis. J Oncol (2010) 1.17
Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. Cancer Res (2009) 1.17
Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Res (2012) 1.14
Rational design of small molecule inhibitors targeting RhoA subfamily Rho GTPases. Chem Biol (2012) 1.13
EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther (2008) 1.13
Regulation of mammary gland branching morphogenesis by EphA2 receptor tyrosine kinase. Mol Biol Cell (2009) 1.13
EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase. Oncogene (2012) 1.12
Hsp90 is an essential regulator of EphA2 receptor stability and signaling: implications for cancer cell migration and metastasis. Mol Cancer Res (2009) 1.10
Eph receptors in breast cancer: roles in tumor promotion and tumor suppression. Breast Cancer Res (2008) 1.10
Angiocrine factors modulate tumor proliferation and motility through EphA2 repression of Slit2 tumor suppressor function in endothelium. Cancer Res (2010) 1.07
The SAM domains of Anks family proteins are critically involved in modulating the degradation of EphA receptors. Mol Cell Biol (2010) 1.04
Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC. J Clin Invest (2014) 1.03
KiSS1 suppresses TNFalpha-induced breast cancer cell invasion via an inhibition of RhoA-mediated NF-kappaB activation. J Cell Biochem (2009) 1.03
Effects of cancer-associated EPHA3 mutations on lung cancer. J Natl Cancer Inst (2012) 1.02
A role for epha2 in cell migration and refractive organization of the ocular lens. Invest Ophthalmol Vis Sci (2012) 1.02
ErbB-2 signals through Plexin-B1 to promote breast cancer metastasis. J Clin Invest (2012) 1.01
Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms. Biochemistry (2012) 1.01
Clinical relevance of Ephs and ephrins in cancer: lessons from breast, colorectal, and lung cancer profiling. Semin Cell Dev Biol (2011) 1.00
EphA receptor signaling--complexity and emerging themes. Semin Cell Dev Biol (2011) 1.00
EphA/ephrin-A signaling is critically involved in region-specific apoptosis during early brain development. Cell Death Differ (2012) 0.99
Integrin-associated CD151 drives ErbB2-evoked mammary tumor onset and metastasis. Neoplasia (2012) 0.99
The multifaceted roles of Eph/ephrin signaling in breast cancer. Cell Adh Migr (2012) 0.98
Regulation of tumor initiation and metastatic progression by Eph receptor tyrosine kinases. Adv Cancer Res (2012) 0.98
Eph receptors and ephrins as targets for cancer therapy. J Cell Mol Med (2012) 0.98
Ligand targeting of EphA2 enhances keratinocyte adhesion and differentiation via desmoglein 1. Mol Biol Cell (2010) 0.97
Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls. J Oncol (2010) 0.97
Guidance molecules in lung cancer. Cell Adh Migr (2010) 0.97
The receptor tyrosine kinase EphA2 is a direct target gene of hypermethylated in cancer 1 (HIC1). J Biol Chem (2011) 0.93
Ena drives invasive macrophage migration in Drosophila embryos. Dis Model Mech (2010) 0.92
Hunk is required for HER2/neu-induced mammary tumorigenesis. J Clin Invest (2011) 0.91
JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility, and cancer stem cell-like properties in non-small cell lung cancer. Cancer Res (2014) 0.91
Clinical significance of EphA2 expression in squamous-cell carcinoma of the head and neck. J Cancer Res Clin Oncol (2010) 0.90
Eph and ephrins in epithelial stem cell niches and cancer. Cell Adh Migr (2012) 0.90
Cooperative signaling between Slit2 and Ephrin-A1 regulates a balance between angiogenesis and angiostasis. Mol Cell Biol (2010) 0.90
Soluble ephrin a1 is necessary for the growth of HeLa and SK-BR3 cells. Cancer Cell Int (2010) 0.89
Host deficiency in Vav2/3 guanine nucleotide exchange factors impairs tumor growth, survival, and angiogenesis in vivo. Mol Cancer Res (2009) 0.89
Downregulation of EphA2 expression suppresses the growth and metastasis in squamous-cell carcinoma of the head and neck in vitro and in vivo. J Cancer Res Clin Oncol (2011) 0.88
EphrinA5-EphA7 complex induces apoptotic cell death via TNFR1. Mol Cells (2013) 0.86
EphA receptors regulate prostate cancer cell dissemination through Vav2-RhoA mediated cell-cell repulsion. Biol Open (2014) 0.86
Navigating breast cancer: axon guidance molecules as breast cancer tumor suppressors and oncogenes. J Mammary Gland Biol Neoplasia (2011) 0.86
Roles of EphA2 in Development and Disease. Genes (Basel) (2013) 0.86
Regulation of endothelial cell proliferation and vascular assembly through distinct mTORC2 signaling pathways. Mol Cell Biol (2015) 0.85
The role of EPH receptors in cancer-related epithelial-mesenchymal transition. Chin J Cancer (2013) 0.85
Regulation of apoptosis in HL-1 cardiomyocytes by phosphorylation of the receptor tyrosine kinase EphA2 and protection by lithocholic acid. Br J Pharmacol (2012) 0.85
EphA2 is a functional receptor for the growth factor progranulin. J Cell Biol (2016) 0.84
Knockdown of EphB1 receptor decreases medulloblastoma cell growth and migration and increases cellular radiosensitization. Oncotarget (2015) 0.84
Eph receptor tyrosine kinases in cancer stem cells. Cytokine Growth Factor Rev (2014) 0.84
EphA2 silencing in nasopharyngeal carcinoma leads to decreased proliferation, invasion and increased sensitization to paclitaxel. Oncol Lett (2012) 0.84
EphB2 activation is required for ependymoma development as well as inhibits differentiation and promotes proliferation of the transformed cell. Sci Rep (2015) 0.84
A loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability. Oncotarget (2016) 0.84
Exploring the link between germline and somatic genetic alterations in breast carcinogenesis. PLoS One (2010) 0.83
Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer. Crit Rev Oncol Hematol (2010) 0.83
EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer. Clin Cancer Res (2015) 0.81
EphA2 enhances the proliferation and invasion ability of LNCaP prostate cancer cells. Oncol Lett (2014) 0.81
Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2. Nat Commun (2015) 0.81
EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Cancer Res (2016) 0.80
EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model. J Gene Med (2012) 0.80
Elevated Slit2 Activity Impairs VEGF-Induced Angiogenesis and Tumor Neovascularization in EphA2-Deficient Endothelium. Mol Cancer Res (2014) 0.80
The Ephrin-A1/EPHA2 Signaling Axis Regulates Glutamine Metabolism in HER2-Positive Breast Cancer. Cancer Res (2016) 0.79
Expression of Eph receptor A10 is correlated with lymph node metastasis and stage progression in breast cancer patients. Cancer Med (2013) 0.79
An integrated genomic approach identifies persistent tumor suppressive effects of transforming growth factor-β in human breast cancer. Breast Cancer Res (2014) 0.79
Design and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cells. Chem Biol (2015) 0.78
VAMP-associated protein B (VAPB) promotes breast tumor growth by modulation of Akt activity. PLoS One (2012) 0.78
When Good Turns Bad: Regulation of Invasion and Metastasis by ErbB2 Receptor Tyrosine Kinase. Cells (2014) 0.78
High EphA2 protein expression in renal cell carcinoma is associated with a poor disease outcome. Oncol Lett (2014) 0.77
mTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling Axis. PLoS Genet (2015) 0.77
Loss of PTPN12 Stimulates Progression of ErbB2-Dependent Breast Cancer by Enhancing Cell Survival, Migration, and Epithelial-to-Mesenchymal Transition. Mol Cell Biol (2015) 0.76
A Modified Adenovirus Vector-Mediated Antibody Screening Method Identifies EphA2 as a Cancer Target. Transl Oncol (2017) 0.76
Anks1a regulates COPII-mediated anterograde transport of receptor tyrosine kinases critical for tumorigenesis. Nat Commun (2016) 0.75
EphA2 Is a Potential Player of Malignant Cellular Behavior in Non-Metastatic Renal Cell Carcinoma Cells but Not in Metastatic Renal Cell Carcinoma Cells. PLoS One (2015) 0.75
Ephrin type‑A receptor 2 regulates sensitivity to paclitaxel in nasopharyngeal carcinoma via the phosphoinositide 3‑kinase/Akt signalling pathway. Mol Med Rep (2014) 0.75
Phosphorylation of Rab-coupling protein by LMTK3 controls Rab14-dependent EphA2 trafficking to promote cell:cell repulsion. Nat Commun (2017) 0.75
Progranulin and the receptor tyrosine kinase EphA2, partners in crime? J Cell Biol (2016) 0.75
EphB4/ephrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins. Int J Med Sci (2016) 0.75
Eph Receptor Tyrosine Kinases in Tumor Immunity. Cancer Res (2016) 0.75
Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers. Oncogene (2017) 0.75
The hallmarks of cancer. Cell (2000) 113.05
A system for stable expression of short interfering RNAs in mammalian cells. Science (2002) 35.21
Cancer genes and the pathways they control. Nat Med (2004) 24.22
Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods (2003) 18.51
Oncogenic kinase signalling. Nature (2001) 16.30
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol (2000) 13.29
Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol (1992) 12.96
Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol (2003) 8.61
Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A (1992) 8.59
Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol (2005) 7.14
ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol (2001) 6.21
An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science (1995) 6.03
Rules for making human tumor cells. N Engl J Med (2002) 4.84
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res (2005) 4.24
Timing of cyclin D1 expression within G1 phase is controlled by Rho. Nat Cell Biol (2001) 3.63
EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res (2001) 3.24
Diverse roles of eph receptors and ephrins in the regulation of cell migration and tissue assembly. Dev Cell (2004) 3.11
Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res (1995) 2.67
The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene (2000) 2.46
The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev (1992) 2.44
Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer (2007) 2.41
Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene (2002) 2.41
A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell (2005) 2.27
Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol (2001) 2.25
'Eph'ective signaling: forward, reverse and crosstalk. J Cell Sci (2003) 2.17
Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Mol Cell Biol (2003) 1.99
EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene (2004) 1.95
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst (2006) 1.87
Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res (2004) 1.84
EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation. J Cell Sci (2004) 1.82
Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. J Biol Chem (2004) 1.72
Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res (2002) 1.70
Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin. Cancer Res (2006) 1.64
Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J (2005) 1.61
A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene (2005) 1.59
c-Cbl-dependent EphA2 protein degradation is induced by ligand binding. Mol Cancer Res (2002) 1.57
Eph receptor tyrosine kinases in angiogenesis: from development to disease. Angiogenesis (2004) 1.55
ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. Mol Cell Biol (2002) 1.55
EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Targets (2005) 1.54
Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility. Mol Cancer Res (2007) 1.52
Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Cancer Gene Ther (2004) 1.49
Signal transduction in mammary tumorigenesis: a transgenic perspective. Oncogene (2000) 1.46
Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res (2004) 1.44
Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-Kinase-dependent Rac1 activation. J Biol Chem (2006) 1.41
Nuclear factor-kappaB (NF-kappaB) regulates proliferation and branching in mouse mammary epithelium. Mol Biol Cell (2001) 1.40
The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia (2001) 1.38
Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr Pharm Des (2004) 1.33
Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer (2002) 1.33
Cell transformation by the middle T-antigen of polyoma virus. Oncogene (2001) 1.31
Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis. Oncogene (2001) 1.31
Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade. Oncogene (2002) 1.30
Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors. Neoplasia (2003) 1.30
Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice. Cancer Res (2006) 1.27
E7-transduced human breast epithelial cells show partial differentiation in three-dimensional culture. Cancer Res (1999) 1.26
Negative regulation of EphA2 receptor by Cbl. Biochem Biophys Res Commun (2002) 1.21
Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells. Cancer (2006) 1.18
Expression profiling of UVB response in melanocytes identifies a set of p53-target genes. J Invest Dermatol (2006) 1.17
Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness. Biochem Biophys Res Commun (2004) 1.15
Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation. Oncogene (2000) 1.08
Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res (2000) 1.07
The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Res Treat (1994) 1.07
Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth. Neoplasia (2006) 1.06
EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. Cancer Res (2003) 1.05
Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer. Surgery (2003) 1.02
EGFR and EGFRvIII expression in primary breast cancer and cell lines. Breast Cancer Res Treat (2004) 0.99
Tumor necrosis factor-alpha induction of endothelial ephrin A1 expression is mediated by a p38 MAPK- and SAPK/JNK-dependent but nuclear factor-kappa B-independent mechanism. J Biol Chem (2001) 0.97
Apoptotic response to 5-fluorouracil treatment is mediated by reduced polyamines, non-autocrine Fas ligand and induced tumor necrosis factor receptor 2. Cancer Biol Ther (2003) 0.95
In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice. Lab Anim Sci (1999) 0.95
A novel mechanism for p53 to regulate its target gene ECK in signaling apoptosis. Mol Cancer Res (2006) 0.91
Ligand binding up-regulates EphA2 messenger RNA through the mitogen-activated protein/extracellular signal-regulated kinase pathway. Mol Cancer Res (2003) 0.80
A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc (2007) 5.15
Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest (2002) 4.64
Pathogenomic sequence analysis of Bacillus cereus and Bacillus thuringiensis isolates closely related to Bacillus anthracis. J Bacteriol (2006) 3.23
Homer binds TRPC family channels and is required for gating of TRPC1 by IP3 receptors. Cell (2003) 3.11
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med (2013) 3.00
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat Med (2011) 2.87
Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA (2012) 2.85
Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. J Am Soc Nephrol (2008) 2.74
A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther (2011) 2.74
Pancreatic islet production of vascular endothelial growth factor--a is essential for islet vascularization, revascularization, and function. Diabetes (2006) 2.53
Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene (2002) 2.41
Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther (2007) 1.97
Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res (2002) 1.96
Acetylation modulates cellular distribution and DNA sensing ability of interferon-inducible protein IFI16. Proc Natl Acad Sci U S A (2012) 1.88
Regulation of osteogenic differentiation during skeletal development. Front Biosci (2008) 1.88
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst (2006) 1.87
A comprehensive analysis of the dual roles of BMPs in regulating adipogenic and osteogenic differentiation of mesenchymal progenitor cells. Stem Cells Dev (2009) 1.87
Seed size, more than nutrient or tannin content, affects seed caching behavior of a common genus of Old World rodents. Ecology (2009) 1.85
EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation. J Cell Sci (2004) 1.82
The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev (2002) 1.80
Comprehensive proteomic profiling of the membrane constituents of a Mycobacterium tuberculosis strain. Mol Cell Proteomics (2003) 1.77
Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem (2005) 1.77
Protein phosphatase 2A dephosphorylation of phosphoserine 112 plays the gatekeeper role for BAD-mediated apoptosis. Mol Cell Biol (2003) 1.75
TRP-ML1 is a lysosomal monovalent cation channel that undergoes proteolytic cleavage. J Biol Chem (2005) 1.75
A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog (2007) 1.74
Mycobacterium tuberculosis functional network analysis by global subcellular protein profiling. Mol Biol Cell (2004) 1.73
The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi's sarcoma–associated herpesvirus. Nat Med (2012) 1.72
Primary leiomyosarcoma of extragnathic bone: clinicopathologic features and reevaluation of prognosis. Arch Pathol Lab Med (2009) 1.63
Molecular and cellular approaches for the detection of protein-protein interactions: latest techniques and current limitations. Plant J (2008) 1.62
Monte Carlo based method for fluorescence tomographic imaging with lifetime multiplexing using time gates. Biomed Opt Express (2011) 1.61
Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J (2005) 1.61
A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene (2005) 1.59
Eph receptor tyrosine kinases in angiogenesis: from development to disease. Angiogenesis (2004) 1.55
EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Targets (2005) 1.54
BMP-9-induced osteogenic differentiation of mesenchymal progenitors requires functional canonical Wnt/beta-catenin signalling. J Cell Mol Med (2008) 1.54
Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects. Lab Invest (2008) 1.54
Wnt signaling and human diseases: what are the therapeutic implications? Lab Invest (2007) 1.51
Contribution of polycomb homologues Bmi-1 and Mel-18 to medulloblastoma pathogenesis. Mol Cell Biol (2007) 1.50
Overexpression of EPHA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism. J Cell Sci (2008) 1.48
Hey1 basic helix-loop-helix protein plays an important role in mediating BMP9-induced osteogenic differentiation of mesenchymal progenitor cells. J Biol Chem (2008) 1.48
Combining Usability Techniques to Design Geovisualization Tools for Epidemiology. Cartogr Geogr Inf Sci (2005) 1.46
High-sensitivity C-reactive protein predicts target organ damage in Chinese patients with metabolic syndrome. Metabolism (2007) 1.45
Kidney transplantation in mice using left and right kidney grafts. J Surg Res (2010) 1.44
Human cytomegalovirus tegument protein pUL83 inhibits IFI16-mediated DNA sensing for immune evasion. Cell Host Microbe (2013) 1.44
Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia. J Exp Med (2012) 1.44
Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res (2009) 1.44
Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation. PLoS One (2010) 1.41
Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-Kinase-dependent Rac1 activation. J Biol Chem (2006) 1.41
The complete genome sequence of Bacillus thuringiensis Al Hakam. J Bacteriol (2007) 1.40
Essential role of Vav family guanine nucleotide exchange factors in EphA receptor-mediated angiogenesis. Mol Cell Biol (2006) 1.37
EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst (2009) 1.37
Predicting mating patterns from pollination syndromes: the case of "sapromyiophily" in Tacca chantrieri (Taccaceae). Am J Bot (2005) 1.36
Ephrin-B1 transduces signals to activate integrin-mediated migration, attachment and angiogenesis. J Cell Sci (2002) 1.36
Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr Pharm Des (2004) 1.33
Full-field time-resolved fluorescence tomography of small animals. Opt Lett (2010) 1.32
A visualization system for space-time and multivariate patterns (VIS-STAMP). IEEE Trans Vis Comput Graph (2006) 1.32
A membrane protein/signaling protein interaction network for Arabidopsis version AMPv2. Front Physiol (2010) 1.30
Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors. Neoplasia (2003) 1.30
Design, synthesis, and biological evaluation of new-generation taxoids. J Med Chem (2008) 1.29
High regeneration capacity helps tropical seeds to counter rodent predation. Oecologia (2011) 1.28
Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice. Cancer Res (2006) 1.27
Development of an optical imaging platform for functional imaging of small animals using wide-field excitation. Biomed Opt Express (2010) 1.26
S-Nitrosylation of DRP1 does not affect enzymatic activity and is not specific to Alzheimer's disease. J Alzheimers Dis (2010) 1.26
Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci U S A (2011) 1.26
Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. Proc Natl Acad Sci U S A (2013) 1.25
Identification and functional analysis of phosphorylated tyrosine residues within EphA2 receptor tyrosine kinase. J Biol Chem (2008) 1.24
Establishment and characterization of a new highly metastatic human osteosarcoma cell line. Clin Exp Metastasis (2009) 1.23
Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome. PLoS One (2011) 1.22
Azoxymethane is a genetic background-dependent colorectal tumor initiator and promoter in mice: effects of dose, route, and diet. Toxicol Sci (2005) 1.21
Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. J Clin Oncol (2011) 1.21
Mechanism-based tumor-targeting drug delivery system. Validation of efficient vitamin receptor-mediated endocytosis and drug release. Bioconjug Chem (2010) 1.19
Scatter-hoarding rodents prefer slightly astringent food. PLoS One (2011) 1.19
Eph receptors and Ephrins in cancer: common themes and controversies. Cancer Res (2008) 1.17
Toward homogeneous erythropoietin: fine tuning of the C-terminal acyl donor in the chemical synthesis of the Cys29-Gly77 glycopeptide domain. J Am Chem Soc (2009) 1.15
Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct. Cancer Res (2007) 1.15
Characterization of gene expression regulated by American ginseng and ginsenoside Rg3 in human colorectal cancer cells. Int J Oncol (2008) 1.15
PP2A activation by beta2-adrenergic receptor agonists: novel regulatory mechanism of keratinocyte migration. J Biol Chem (2003) 1.13
Regulation of mammary gland branching morphogenesis by EphA2 receptor tyrosine kinase. Mol Biol Cell (2009) 1.13
Syntheses and evaluation of novel fatty acid-second-generation taxoid conjugates as promising anticancer agents. Bioorg Med Chem Lett (2005) 1.12
Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J Pathol (2012) 1.11
Dynamic changes in the microRNA expression profile reveal multiple regulatory mechanisms in the spinal nerve ligation model of neuropathic pain. PLoS One (2011) 1.10
Quantitative tomographic imaging of intermolecular FRET in small animals. Biomed Opt Express (2012) 1.10
Eph receptors in breast cancer: roles in tumor promotion and tumor suppression. Breast Cancer Res (2008) 1.10
Inhibition of retinal neovascularization by soluble EphA2 receptor. Exp Eye Res (2005) 1.10